Share Price and Basic Stock Data
Last Updated: January 17, 2026, 6:26 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Astec Lifesciences Ltd operates within the agrochemicals and pesticides sector, with its current market capitalization reported at ₹1,430 Cr and a share price of ₹642. The company’s revenue performance has shown significant volatility, with sales reported at ₹628 Cr for FY 2023, declining to ₹458 Cr in FY 2024, and further to ₹381 Cr in FY 2025. This trend reflects a concerning decrease in operational effectiveness and market demand. Quarterly sales figures indicate a peak of ₹200 Cr in September 2022, which subsequently fell to ₹111 Cr by September 2023, and a dismal ₹51 Cr in December 2023. The company’s operating profit margins (OPM) have also fluctuated sharply, recording negative margins in the past two quarters, signaling challenges in cost management and pricing strategies. This decline in revenues and profitability raises questions about the company’s competitive positioning in the agrochemical market, especially against peers who may be performing better amid changing agricultural demands.
Profitability and Efficiency Metrics
Astec Lifesciences has faced severe profitability challenges, as evidenced by its net profit standing at a loss of ₹114 Cr for FY 2025, in stark contrast to a net profit of ₹26 Cr in FY 2023. The operating profit margin has plummeted to -9% in the latest quarter, reflecting a critical need for operational restructuring. The interest coverage ratio (ICR) has also deteriorated to -1.65x, indicating that the company is unable to cover its interest expenses through operational earnings, which raises potential liquidity concerns. The return on equity (ROE) remains relatively high at 45.3%, but this figure is misleading, given the substantial losses; it reflects the equity base rather than operational success. Moreover, the cash conversion cycle (CCC) of 237 days highlights inefficiencies in cash management, with high debtor and inventory days contributing to a strained liquidity position. Overall, these metrics suggest that Astec Lifesciences must address operational inefficiencies to restore profitability and investor confidence.
Balance Sheet Strength and Financial Ratios
Astec Lifesciences’ balance sheet reflects a challenging financial landscape, with total borrowings reported at ₹367 Cr against reserves of ₹392 Cr. The debt-to-equity ratio stands at 2.36x, indicating high leverage that could pose risks in a downturn. The company’s book value per share has declined to ₹119.70, down from ₹214.00 in FY 2023, highlighting a reduction in net asset value. Furthermore, Astec’s current ratio of 0.93x suggests potential liquidity issues, as it falls below the industry benchmark of 1.0x. The company has also recorded a negative return on capital employed (ROCE) of -13%, which indicates that it is not generating sufficient returns on its investments, further straining its financial stability. The enterprise value (EV) of ₹1,875.49 Cr, combined with a market capitalization of ₹1,430 Cr, suggests that investors are wary of the company’s future profitability. Overall, these figures indicate that Astec Lifesciences must take immediate steps to improve its financial health and operational efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Astec Lifesciences reveals a strong promoter holding of 72.42%, which indicates a significant level of confidence from the company’s founders in its long-term prospects. However, foreign institutional investors (FIIs) have decreased their stake to 0%, while domestic institutional investors (DIIs) hold only 4.01%. The overall public shareholding stands at 23.57%, reflecting a cautious sentiment among retail investors. The decline in FII interest from 2.19% in December 2022 to 0% in September 2025 raises concerns about international confidence in the company’s future performance. The number of shareholders has also decreased from 19,545 in December 2022 to 18,276 in September 2025, suggesting a trend of disinterest or disillusionment among retail investors. This lack of diversified institutional backing could pose challenges for Astec Lifesciences in terms of capital raising and market perception, particularly in a competitive sector where investor confidence is crucial.
Outlook, Risks, and Final Insight
Astec Lifesciences faces a myriad of challenges that could impede its recovery and growth trajectory. The substantial decline in sales and profitability, paired with high leverage, presents a significant risk. Additionally, operational inefficiencies indicated by the negative operating profit margins and high cash conversion cycle need urgent attention. However, the strong promoter holding could provide stability and a commitment to turnaround efforts. If the company can successfully implement operational improvements and regain market demand, there may be potential for recovery. Conversely, continued losses could lead to further deterioration in investor sentiment and financial stability. The outlook hinges on the management’s ability to navigate these challenges effectively, restore operational efficiency, and ultimately, regain investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 4,997 Cr. | 1,158 | 2,114/1,110 | 12.4 | 487 | 0.52 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 800 Cr. | 237 | 391/165 | 16.4 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 55.2 Cr. | 106 | 149/56.6 | 9.90 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,893 Cr. | 223 | 331/198 | 109 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 1,052 Cr. | 29.6 | 38.0/16.3 | 82.2 | 22.8 | 0.67 % | 12.9 % | 9.95 % | 1.00 |
| Industry Average | 10,938.65 Cr | 1,095.53 | 31.74 | 369.04 | 0.45% | 15.21% | 19.87% | 6.67 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 200 | 117 | 127 | 143 | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 | 74 |
| Expenses | 166 | 105 | 122 | 140 | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 | 80 |
| Operating Profit | 33 | 12 | 5 | 3 | -3 | -18 | 13 | -46 | -20 | -6 | 6 | -11 | -7 |
| OPM % | 17% | 10% | 4% | 2% | -3% | -36% | 8% | -67% | -20% | -6% | 5% | -12% | -9% |
| Other Income | 4 | 4 | 3 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 |
| Interest | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 | 8 |
| Depreciation | 8 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 | 10 |
| Profit before tax | 25 | 1 | -6 | -11 | -18 | -32 | -1 | -62 | -39 | -25 | -16 | -33 | -24 |
| Tax % | 25% | 31% | -20% | -26% | -24% | -24% | 4% | -36% | 0% | 61% | 3% | 0% | 0% |
| Net Profit | 18 | 1 | -5 | -8 | -13 | -24 | -1 | -40 | -39 | -40 | -16 | -33 | -24 |
| EPS in Rs | 8.17 | 0.38 | -2.22 | -3.66 | -6.00 | -10.86 | -0.43 | -17.73 | -17.21 | -18.03 | -7.18 | -14.75 | -10.96 |
Last Updated: January 13, 2026, 1:21 am
Below is a detailed analysis of the quarterly data for Astec Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Jun 2025) to 74.00 Cr., marking a decrease of 17.00 Cr..
- For Expenses, as of Sep 2025, the value is 80.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 102.00 Cr. (Jun 2025) to 80.00 Cr., marking a decrease of 22.00 Cr..
- For Operating Profit, as of Sep 2025, the value is -7.00 Cr.. The value appears strong and on an upward trend. It has increased from -11.00 Cr. (Jun 2025) to -7.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Sep 2025, the value is -9.00%. The value appears strong and on an upward trend. It has increased from -12.00% (Jun 2025) to -9.00%, marking an increase of 3.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Interest, as of Sep 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.00 Cr. (Jun 2025) to 8.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.00 Cr. (Jun 2025) to 10.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -24.00 Cr.. The value appears strong and on an upward trend. It has increased from -33.00 Cr. (Jun 2025) to -24.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -24.00 Cr.. The value appears strong and on an upward trend. It has increased from -33.00 Cr. (Jun 2025) to -24.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -10.96. The value appears strong and on an upward trend. It has increased from -14.75 (Jun 2025) to -10.96, marking an increase of 3.79.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 207 | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 378 |
| Expenses | 171 | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | 396 |
| Operating Profit | 35 | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -18 |
| OPM % | 17% | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1% | -17% | -5% |
| Other Income | -0 | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 4 |
| Interest | 9 | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 40 |
| Depreciation | 15 | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 |
| Profit before tax | 11 | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -98 |
| Tax % | 22% | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | -24% | -4% | |
| Net Profit | 9 | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -114 |
| EPS in Rs | 4.09 | 6.66 | 2.24 | 8.57 | 15.65 | 16.03 | 21.21 | 29.04 | 40.12 | 11.41 | -20.95 | -60.16 | -50.92 |
| Dividend Payout % | 21% | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 66.67% | -66.67% | 280.00% | 84.21% | 2.86% | 33.33% | 35.42% | 38.46% | -71.11% | -280.77% | -187.23% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 346.67% | -195.79% | -81.35% | 30.48% | 2.08% | 3.04% | -109.57% | -209.66% | 93.54% |
Astec Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -6% |
| 3 Years: | -17% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -7% |
| 3 Years: | -23% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | -14% |
| Last Year: | -45% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
| Reserves | 95 | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 | 392 |
| Borrowings | 83 | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | 367 |
| Other Liabilities | 88 | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | 102 |
| Total Liabilities | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 883 |
| Fixed Assets | 132 | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 500 |
| CWIP | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 146 | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | 383 |
| Total Assets | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 883 |
Below is a detailed analysis of the balance sheet data for Astec Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Mar 2025) to 22.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 392.00 Cr.. The value appears strong and on an upward trend. It has increased from 215.00 Cr. (Mar 2025) to 392.00 Cr., marking an increase of 177.00 Cr..
- For Borrowings, as of Sep 2025, the value is 367.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 555.00 Cr. (Mar 2025) to 367.00 Cr., marking a decrease of 188.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 92.00 Cr. (Mar 2025) to 102.00 Cr., marking an increase of 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 883.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 881.00 Cr. (Mar 2025) to 883.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 500.00 Cr.. The value appears strong and on an upward trend. It has increased from 499.00 Cr. (Mar 2025) to 500.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 21.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 383.00 Cr.. The value appears strong and on an upward trend. It has increased from 361.00 Cr. (Mar 2025) to 383.00 Cr., marking an increase of 22.00 Cr..
- For Total Assets, as of Sep 2025, the value is 883.00 Cr.. The value appears strong and on an upward trend. It has increased from 881.00 Cr. (Mar 2025) to 883.00 Cr., marking an increase of 2.00 Cr..
Notably, the Reserves (392.00 Cr.) exceed the Borrowings (367.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -48.00 | -39.00 | -95.00 | -64.00 | -56.00 | -100.00 | -14.00 | -75.00 | -125.00 | -264.00 | -500.00 | -621.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 |
| Inventory Days | 192 | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 |
| Days Payable | 114 | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 |
| Cash Conversion Cycle | 168 | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 |
| Working Capital Days | 23 | 19 | -28 | 1 | -8 | -2 | 8 | 4 | 12 | -17 | -1 | -26 |
| ROCE % | 11% | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 526,867 | 0.06 | 44.15 | 468,589 | 2025-12-08 04:51:58 | 12.44% |
| ICICI Prudential Commodities Fund | 128,411 | 0.34 | 10.76 | 112,360 | 2025-12-08 04:51:58 | 14.29% |
| ICICI Prudential MidCap Fund | 18,107 | 0.02 | 1.52 | 15,844 | 2025-12-08 00:51:54 | 14.28% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.87 | 33.23 |
| Diluted EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| Cash EPS (Rs.) | -46.40 | -5.42 | 30.22 | 63.39 | 46.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Revenue From Operations / Share (Rs.) | 194.43 | 233.66 | 320.40 | 345.23 | 283.28 |
| PBDIT / Share (Rs.) | -30.89 | -0.13 | 45.56 | 83.96 | 61.00 |
| PBIT / Share (Rs.) | -53.18 | -18.62 | 28.39 | 66.43 | 47.90 |
| PBT / Share (Rs.) | -71.89 | -31.49 | 17.82 | 61.81 | 45.47 |
| Net Profit / Share (Rs.) | -68.69 | -23.91 | 13.05 | 45.86 | 33.22 |
| NP After MI And SOA / Share (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| PBDIT Margin (%) | -15.88 | -0.05 | 14.21 | 24.31 | 21.53 |
| PBIT Margin (%) | -27.35 | -7.97 | 8.86 | 19.24 | 16.90 |
| PBT Margin (%) | -36.97 | -13.47 | 5.56 | 17.90 | 16.05 |
| Net Profit Margin (%) | -35.32 | -10.23 | 4.07 | 13.28 | 11.72 |
| NP After MI And SOA Margin (%) | -35.33 | -10.24 | 4.06 | 13.28 | 11.72 |
| Return on Networth / Equity (%) | -57.40 | -12.70 | 6.09 | 22.66 | 21.03 |
| Return on Capital Employeed (%) | -20.22 | -6.32 | 12.28 | 32.05 | 26.40 |
| Return On Assets (%) | -15.28 | -4.81 | 2.61 | 10.02 | 9.60 |
| Long Term Debt / Equity (X) | 1.19 | 0.53 | 0.02 | 0.00 | 0.12 |
| Total Debt / Equity (X) | 2.36 | 1.34 | 0.81 | 0.70 | 0.60 |
| Asset Turnover Ratio (%) | 0.41 | 0.46 | 0.66 | 0.85 | 0.88 |
| Current Ratio (X) | 0.93 | 1.00 | 0.94 | 1.05 | 1.03 |
| Quick Ratio (X) | 0.49 | 0.51 | 0.38 | 0.67 | 0.69 |
| Inventory Turnover Ratio (X) | 2.14 | 1.30 | 1.91 | 3.04 | 3.03 |
| Dividend Payout Ratio (NP) (%) | 0.00 | -6.26 | 11.50 | 3.26 | 4.51 |
| Dividend Payout Ratio (CP) (%) | 0.00 | -27.54 | 4.96 | 2.36 | 3.23 |
| Earning Retention Ratio (%) | 0.00 | 106.26 | 88.50 | 96.74 | 95.49 |
| Cash Earning Retention Ratio (%) | 0.00 | 127.54 | 95.04 | 97.64 | 96.77 |
| Interest Coverage Ratio (X) | -1.65 | -0.01 | 4.31 | 18.17 | 25.15 |
| Interest Coverage Ratio (Post Tax) (X) | -2.67 | -0.85 | 2.24 | 10.92 | 14.69 |
| Enterprise Value (Cr.) | 1875.49 | 2574.29 | 3049.60 | 3711.79 | 2144.94 |
| EV / Net Operating Revenue (X) | 4.92 | 5.62 | 4.85 | 5.49 | 3.87 |
| EV / EBITDA (X) | -30.96 | -9580.53 | 34.14 | 22.56 | 17.95 |
| MarketCap / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| Retention Ratios (%) | 0.00 | 106.26 | 88.49 | 96.73 | 95.48 |
| Price / BV (X) | 5.64 | 5.64 | 6.46 | 8.66 | 6.34 |
| Price / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| EarningsYield | -0.10 | -0.02 | 0.01 | 0.02 | 0.03 |
After reviewing the key financial ratios for Astec Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Diluted EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Cash EPS (Rs.), as of Mar 25, the value is -46.40. This value is below the healthy minimum of 3. It has decreased from -5.42 (Mar 24) to -46.40, marking a decrease of 40.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 194.43. It has decreased from 233.66 (Mar 24) to 194.43, marking a decrease of 39.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -30.89. This value is below the healthy minimum of 2. It has decreased from -0.13 (Mar 24) to -30.89, marking a decrease of 30.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is -53.18. This value is below the healthy minimum of 0. It has decreased from -18.62 (Mar 24) to -53.18, marking a decrease of 34.56.
- For PBT / Share (Rs.), as of Mar 25, the value is -71.89. This value is below the healthy minimum of 0. It has decreased from -31.49 (Mar 24) to -71.89, marking a decrease of 40.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -68.69. This value is below the healthy minimum of 2. It has decreased from -23.91 (Mar 24) to -68.69, marking a decrease of 44.78.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 2. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For PBDIT Margin (%), as of Mar 25, the value is -15.88. This value is below the healthy minimum of 10. It has decreased from -0.05 (Mar 24) to -15.88, marking a decrease of 15.83.
- For PBIT Margin (%), as of Mar 25, the value is -27.35. This value is below the healthy minimum of 10. It has decreased from -7.97 (Mar 24) to -27.35, marking a decrease of 19.38.
- For PBT Margin (%), as of Mar 25, the value is -36.97. This value is below the healthy minimum of 10. It has decreased from -13.47 (Mar 24) to -36.97, marking a decrease of 23.50.
- For Net Profit Margin (%), as of Mar 25, the value is -35.32. This value is below the healthy minimum of 5. It has decreased from -10.23 (Mar 24) to -35.32, marking a decrease of 25.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -35.33. This value is below the healthy minimum of 8. It has decreased from -10.24 (Mar 24) to -35.33, marking a decrease of 25.09.
- For Return on Networth / Equity (%), as of Mar 25, the value is -57.40. This value is below the healthy minimum of 15. It has decreased from -12.70 (Mar 24) to -57.40, marking a decrease of 44.70.
- For Return on Capital Employeed (%), as of Mar 25, the value is -20.22. This value is below the healthy minimum of 10. It has decreased from -6.32 (Mar 24) to -20.22, marking a decrease of 13.90.
- For Return On Assets (%), as of Mar 25, the value is -15.28. This value is below the healthy minimum of 5. It has decreased from -4.81 (Mar 24) to -15.28, marking a decrease of 10.47.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has increased from 0.53 (Mar 24) to 1.19, marking an increase of 0.66.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.36. This value exceeds the healthy maximum of 1. It has increased from 1.34 (Mar 24) to 2.36, marking an increase of 1.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.41. It has decreased from 0.46 (Mar 24) to 0.41, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 0.93. This value is below the healthy minimum of 1.5. It has decreased from 1.00 (Mar 24) to 0.93, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.51 (Mar 24) to 0.49, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.14. This value is below the healthy minimum of 4. It has increased from 1.30 (Mar 24) to 2.14, marking an increase of 0.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -6.26 (Mar 24) to 0.00, marking an increase of 6.26.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -27.54 (Mar 24) to 0.00, marking an increase of 27.54.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 127.54 (Mar 24) to 0.00, marking a decrease of 127.54.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.65. This value is below the healthy minimum of 3. It has decreased from -0.01 (Mar 24) to -1.65, marking a decrease of 1.64.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.67. This value is below the healthy minimum of 3. It has decreased from -0.85 (Mar 24) to -2.67, marking a decrease of 1.82.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,875.49. It has decreased from 2,574.29 (Mar 24) to 1,875.49, marking a decrease of 698.80.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 5.62 (Mar 24) to 4.92, marking a decrease of 0.70.
- For EV / EBITDA (X), as of Mar 25, the value is -30.96. This value is below the healthy minimum of 5. It has increased from -9,580.53 (Mar 24) to -30.96, marking an increase of 9,549.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Price / BV (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 5.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For EarningsYield, as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has decreased from -0.02 (Mar 24) to -0.10, marking a decrease of 0.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astec Lifesciences Ltd:
- Net Profit Margin: -35.32%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -20.22% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -57.4% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.67
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 31.74)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.36
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -35.32%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Godrej One, 3rd Floor, Pirojshanagar, Mumbai Maharashtra 400079 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nadir B Godrej | Chairman |
| Mr. Burjis N Godrej | Managing Director |
| Mr. Balram Singh Yadav | Non Executive Director |
| Mr. Ashok V Hiremath | Non Executive Director |
| Dr. Ganapati Yadav | Independent Director |
| Mr. R R Govindan | Independent Director |
| Mr. Nandkumar Dhekne | Independent Director |
| Ms. Anjali Gupte | Independent Director |
FAQ
What is the intrinsic value of Astec Lifesciences Ltd?
Astec Lifesciences Ltd's intrinsic value (as of 17 January 2026) is ₹417.44 which is 35.78% lower the current market price of ₹650.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,448 Cr. market cap, FY2025-2026 high/low of ₹1,042/607, reserves of ₹392 Cr, and liabilities of ₹883 Cr.
What is the Market Cap of Astec Lifesciences Ltd?
The Market Cap of Astec Lifesciences Ltd is 1,448 Cr..
What is the current Stock Price of Astec Lifesciences Ltd as on 17 January 2026?
The current stock price of Astec Lifesciences Ltd as on 17 January 2026 is ₹650.
What is the High / Low of Astec Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astec Lifesciences Ltd stocks is ₹1,042/607.
What is the Stock P/E of Astec Lifesciences Ltd?
The Stock P/E of Astec Lifesciences Ltd is .
What is the Book Value of Astec Lifesciences Ltd?
The Book Value of Astec Lifesciences Ltd is 186.
What is the Dividend Yield of Astec Lifesciences Ltd?
The Dividend Yield of Astec Lifesciences Ltd is 0.00 %.
What is the ROCE of Astec Lifesciences Ltd?
The ROCE of Astec Lifesciences Ltd is 12.9 %.
What is the ROE of Astec Lifesciences Ltd?
The ROE of Astec Lifesciences Ltd is 45.3 %.
What is the Face Value of Astec Lifesciences Ltd?
The Face Value of Astec Lifesciences Ltd is 10.0.